StockData
Nektar Therapeutics logo

Nektar Therapeutics (NKTR) stock

NKTRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q4 FY2025, quarter ended Dec 31, 2025Last filing: 10-Q on Nov 13, 2026Score 9/30
$34.42−1.49 (-4.15%)

Close on Nov 18, 2026Market cap $1.18BP/E –Yield –

Nektar Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Nektar Therapeutics's operating income for the twelve months ending Dec 31, 2025 was -$140.10M. For fiscal 2025 it was -$140.10M. The highest annual figure on record is $687.93M in fiscal 2018.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$140.10M–
FY2024Dec 31, 2024-$105.20M–
FY2023Dec 31, 2023-$263.68M–
FY2022Dec 31, 2022-$376.17M–
FY2021Dec 31, 2021-$446.10M–
FY2020Dec 31, 2020-$425.11M–
FY2019Dec 31, 2019-$440.04M-164.0%
FY2018Dec 31, 2018$687.93M–
FY2017Dec 31, 2017-$59.64M–
FY2016Dec 31, 2016-$112.86M–
FY2015Dec 31, 2015-$29.37M–
FY2014Dec 31, 2014-$16.49M–
FY2013Dec 31, 2013-$120.13M–
FY2012Dec 31, 2012-$141.20M–
FY2011Dec 31, 2011-$123.94M–
FY2010Dec 31, 2010-$28.26M–
FY2009Dec 31, 2009-$95.13M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025-$27.67M-292.8%
Q3 FY2025Sep 30, 2025-$31.67M–
Q2 FY2025Jun 30, 2025-$36.23M–
Q1 FY2025Mar 31, 2025-$44.54M–
Q4 FY2024Dec 31, 2024$14.35M–
Q3 FY2024Sep 30, 2024-$34.35M–
Q2 FY2024Jun 30, 2024-$49.77M–
Q1 FY2024Mar 31, 2024-$35.43M–
Q4 FY2023Dec 31, 2023-$33.51M–
Q3 FY2023Sep 30, 2023-$44.86M–
Q2 FY2023Jun 30, 2023-$50.60M–
Q1 FY2023Mar 31, 2023-$134.71M–
Q4 FY2022Dec 31, 2022-$52.47M–
Q3 FY2022Sep 30, 2022-$54.30M–
Q2 FY2022Jun 30, 2022-$152.84M–
Q1 FY2022Mar 31, 2022-$116.56M–
Q4 FY2021Dec 31, 2021-$112.91M–
Q3 FY2021Sep 30, 2021-$113.60M–
Q2 FY2021Jun 30, 2021-$110.21M–
Q1 FY2021Mar 31, 2021-$109.39M–
Q4 FY2020Dec 31, 2020-$110.72M–
Q3 FY2020Sep 30, 2020-$103.05M–
Q2 FY2020Jun 30, 2020-$77.71M–
Q1 FY2020Mar 31, 2020-$133.63M–
Q4 FY2019Dec 31, 2019-$109.64M–
Q3 FY2019Sep 30, 2019-$98.74M–
Q2 FY2019Jun 30, 2019-$110.97M-111.4%
Q1 FY2019Mar 31, 2019-$120.69M–
Q4 FY2018Dec 31, 2018-$100.30M–
Q3 FY2018Sep 30, 2018-$98.63M-242.0%
Q2 FY2018Jun 30, 2018$973.60M–
Q1 FY2018Mar 31, 2018-$86.74M–
Q4 FY2017Dec 31, 2017-$24.03M–
Q3 FY2017Sep 30, 2017$69.49M–
Q2 FY2017Jun 30, 2017-$50.66M–
Q1 FY2017Mar 31, 2017-$54.44M–
Q4 FY2016Dec 31, 2016-$32.15M–
Q3 FY2016Sep 30, 2016-$32.90M–
Q2 FY2016Jun 30, 2016-$38.33M–

More Nektar Therapeutics figures

See a number that looks wrong?